Lumosa Therapeutics Co., Ltd. (Lumosa) and AMed Co., Ltd. (AMed) signed an agreement on June 8th, 2018, for the licensing rights of LT1001, an extended-release analgesic injection (Product), in Southeast Asian market. AMed received the exclusive rights to submit drug registration, technological licensing, market development and sales for the Product in Indonesia, Malaysia, Philippines, Thailand, Singapore, Brunei, Cambodia, Laos, Myanmar, and Vietnam. The amount for milestone payments and royalties depend on the registration approval and sales performance of the Product. Lumosa received an notification from AMed regarding the receipt of an import permit from Thai Food and Drug Administration for Naldebain, an extend-release analgesic injection.